1.44
+0.045(+3.24%)
Currency In USD
| Previous Close | 1.39 |
| Open | 1.39 |
| Day High | 1.44 |
| Day Low | 1.39 |
| 52-Week High | 5.01 |
| 52-Week Low | 1 |
| Volume | 845 |
| Average Volume | 107,252 |
| Market Cap | 13.33M |
| PE | -0.39 |
| EPS | -3.68 |
| Moving Average 50 Days | 1.59 |
| Moving Average 200 Days | 2.7 |
| Change | 0.05 |
If you invested $1000 in SAB Biotherapeutics, Inc. (SABS) since IPO date, it would be worth $14.14 as of April 17, 2025 at a share price of $1.435. Whereas If you bought $1000 worth of SAB Biotherapeutics, Inc. (SABS) shares 3 years ago, it would be worth $54.98 as of April 17, 2025 at a share price of $1.435.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
SAB BIO Reports Full Year 2024 Operating and Financial Results
GlobeNewswire Inc.
Mar 31, 2025 11:32 AM GMT
SAB-142 Phase 1 trial positive topline data announced at KOL eventMIAMI, March 31, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is
SAB BIO to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Jan 31, 2025 12:00 PM GMT
MIAMI, Jan. 31, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing SAB-142, a human anti-thymocyte immunoglobulin (hIgG) t
SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142
GlobeNewswire Inc.
Jan 28, 2025 12:00 PM GMT
SAB-142 was generally well-tolerated among healthy volunteers; data from Phase 1 trial confirms SAB-142 does not cause serum sickness or anti-drug antibodies at target dose Study results support that SAB-142 is well-positioned for re-dosing in outpat